Acquired Company
Forbion European Acquisition Corp completed its business combination with enGene Inc., resulting in enGene Holdings Inc. becoming a publicly traded company with ENGN trading on Nasdaq beginning November 1, 2023.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada. Show more
Location: 4868 Rue Levy, Montreal, QC, H4R 2P1, Canada | Website: https://www.engene.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
652.4M
52 Wk Range
$2.65 - $12.25
Previous Close
$9.74
Open
$9.71
Volume
1,164
Day Range
$9.52 - $9.80
Enterprise Value
490.5M
Cash
193.7M
Avg Qtr Burn
-24.81M
Insider Ownership
0.09%
Institutional Own.
86.53%
Qtr Updated
10/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Detalimogene (EG-70) Details Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 Data readout |